A

AstraZeneca

Global pharmaceutical company developing prescription medicines

Senior Manager Marketing Capability & Digital Learning

Full-TimeUpdated on 10/14/2026Deadline 10/31/26
No salary listed
Expert
Bachelor's, MBA, Certification
China
In Person
TrainingInstructional Design & Curriculum Development

About the job

Requirements
  • A bachelor's degree or above in Marketing, Business, Life Sciences, Pharmacy, Medicine, Learning Sciences, or a related discipline.
  • Eight to twelve years of experience in pharmaceutical or healthcare marketing, Commercial Excellence, or capability development, including substantial hands-on contribution to Marketing capability programs.
  • At least three to five years in core pharmaceutical marketing work, such as brand management, launch, indication expansion, lifecycle strategy, market insights, omnichannel marketing, or customer experience.
  • Demonstrated experience designing and implementing end-to-end learning solutions for pharmaceutical Marketing audiences, from needs diagnosis and curriculum design through facilitation, reinforcement, assessment, and impact evaluation.
  • Proven hands-on experience contributing to cross-business-unit or nationwide programs, digital learning products, or learning-platform initiatives involving multiple internal and external stakeholders.
Responsibilities
  • Support capability assessment and gap analysis for pharmaceutical Marketing roles; contribute to refining role- and level-specific capability frameworks, learning paths, skill standards, and certification criteria; translate business priorities into practical capability development solutions.
  • Conduct stakeholder interviews, learner research, and performance analysis to identify capability gaps linked to portfolio strategy, brand lifecycle, launch milestones, healthcare professional and patient insights, and evolving channel models.
  • Apply adult learning and instructional design principles to create end-to-end learning journeys, including pre-learning, workshops, virtual learning, simulations, action learning, stretch assignments, coaching reinforcement, and post-program application activities.
  • Develop and maintain practical pharmaceutical Marketing learning solutions in brand strategy, insight generation, segmentation and targeting, positioning and messaging, launch excellence, lifecycle management, omnichannel engagement, content excellence, campaign planning, customer experience, data-driven decision making, and compliant healthcare professional and patient communication.
  • Translate learner and business needs into learner personas, experience maps, digital product requirements, content architecture, and acceptance criteria; design mobile-first microlearning, scenario-based modules, interactive cases, virtual practice, gamified learning, social learning, and performance-support tools embedded in the flow of work.
  • Create, curate, and continuously improve digital learning assets; apply multimedia and interaction design principles; coordinate content review, localization, publishing, version control, and retirement.
  • Explore and apply generative AI and simulation technologies to content development, learning personalization, conversational practice, and formative assessment; incorporate appropriate human review, quality, privacy, intellectual property, and compliance controls.
  • Collaborate with Digital, IT, and vendors to improve learner experience, content taxonomy, metadata, search and recommendation logic, platform adoption, and operational efficiency; contribute user requirements and test new or enhanced functionality.
  • Design knowledge tests, business cases, simulations, and practical assignments; define measures across reach, engagement, proficiency, application, efficiency, and business impact; analyze dashboards and recommend evidence-based improvements.
  • Coordinate pilots and scaled implementation across business units; support stakeholder readiness, faculty enablement, communications, learner engagement, implementation tracking, and issue resolution.
  • Apply scientific and medical accuracy, promotional review, accessibility, data privacy, copyright and intellectual property, controlled content lifecycle, and archival requirements to all learning solutions.
  • Co-create solutions with Marketing, Medical, Sales, Market Access, Business Excellence, HR/L&D, Digital/IT, Legal, and Compliance; facilitate alignment and translate stakeholder input into clear deliverables.
  • Support RFP development, vendor evaluation, scope definition, contracting, budget tracking, quality assurance, risk identification, and delivery acceptance for assigned learning programs.
Desired Qualifications
  • MBA or relevant credentials in L&D, digital learning, product management, or project management.

About the company

A

AstraZeneca

View
Website

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Massachusetts expansion adds nearly 2,000 scientists and expands workforce over 50% by 2026.
  • H1 2026 revenue rose 6% to $30.7 billion, driven by oncology growth.
  • FLAURA2 and CLARITY-Gastric01 strengthened Tagrisso and sonesitatug vedotin in 2026.

What critics are saying

  • Farxiga faced US and Japan generic competition, plus China VBP, in H1 2026.
  • Forxiga patent fights continue in France, Poland, Portugal, and Australia through 2027.
  • Tagrisso dependence stays acute; one patent loss or trial failure would crush growth.

What makes AstraZeneca unique

  • Pascal Soriot doubled down on oncology, opening Cambridge R&D center October 5, 2026.
  • AstraZeneca's ADC and bispecific platform drove the $2 billion Summit Therapeutics deal September 28, 2026.
  • Tagrisso, Imfinzi, and rare disease franchises keep AstraZeneca diversified across high-value therapeutic categories.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

6%

2 year growth

6%
TelecomTV
Oct 16th, 2026
Sferical One: Ericsson and partners make AI supercomputing a reality in Sweden.

Sferical One: Ericsson and partners make AI supercomputing a reality in Sweden. Oct 16, 2026 * Ericsson is among several major Swedish companies who have started to utilise a new sovereign AI supercomputer in Sweden, called Sferical One, officially launched today by the Sferical AI initiative. As a founding member of Sferical AI - alongside AstraZeneca, Saab, SEB and Wallenberg Investments, with SKF as a strategic partner - Ericsson gains access to secure, sovereign Swedish computing capacity to develop, deliver, and deploy advanced AI solutions alongside the partner companies. The initiative aims to deliver direct societal benefits to Sweden as AI use case momentum gathers pace. Shared use of investment, capacity and expertise under the Sferical AI initiative means the partners can scale AI development faster. Ericsson will contribute telecom expertise, drive AI use cases, and jointly develop a secure, sovereign AI platform, while simultaneously using the platform to further develop Ericsson's own network and automation capabilities. The system is an NVIDIA DGX SuperPOD built on NVIDIA DGX GB300 systems. The system has been running since late summer 2026. Sferical AI will also build services based on NVIDIA Nemotron open multimodal AI models. Today's event was attended by senior executives from Sferical AI, the Swedish partner companies, including Ericsson President and CEO, Per Narvinger, and Nvidia founder and CEO, Jensen Huang. Ericsson CTO, Erik Ekudden, who led Ericsson's co-development of Sferical from inception, says: "I envision the future as a 6G/AI intelligent fabric - a universal framework which enables different AI systems to work together securely and with reliable performance, no matter where they are or who built them. Ensuring a robust and secure infrastructure requires best in class AI models. To build those, we need the best compute infrastructure. Through our cooperation with Sferical we get access to sovereign infrastructure for model training and refinement." Addressing the partner companies at the Sferical One launch, Jensen Huang predicted an exciting future. "You have done the hardest part... you have started," he said. Ericsson's Sferical One engagement to date relates to ensuring secure and reliable networks through AI-based network operations. Jenny Nordlöw, CEO, Sferical AI, says: "Sferical One enables the companies to train and run AI models at a larger scale on a sovereign platform. What makes Sferical unique isn't just the technology, but that several of Sweden's largest companies share the same infrastructure, develop solutions together and share knowledge across industries." Marcus Wallenberg, Chair of Wallenberg Investments, says: "AI will be a critical component of Swedish industry's future competitiveness. Sferical One will help some of Sweden's leading companies stay at the forefront of that development. It is a long-term investment in the capabilities and expertise we will need to compete in the future."

Tech in Asia
Oct 16th, 2026
AstraZeneca strikes $1.5b AI drug discovery deal with Insitro.

AstraZeneca strikes $1.5b AI drug discovery deal with Insitro. AstraZeneca said it partnered with insitro, a California-based AI drug discovery startup, on October 15 to find and develop treatments for metabolic dysfunction-associated steatohepatitis, or MASH, and cardiomyopathies. Insitro will use machine learning and lab-grown cell models to identify the diseases' underlying biology and advance targets selected by AstraZeneca to the development-candidate stage. AstraZeneca will then fund and run future clinical trials. AstraZeneca will pay insitro US$40 million upfront. The startup could also receive up to about US$1.46 billion in development and commercial milestone payments, plus single-digit percentage royalties on future sales. The agreement adds to insitro's existing partnerships with Bristol Myers Squibb and Eli Lilly. It also comes after the US Food and Drug Administration (FDA) approved a treatment for MASH in 2024. Recent AstraZeneca developments. Stay updated on the go with our mobile app. Get latest insights with smoother, more personalized experience through TIA mobile app. How would you feel if you could no longer use Tech in Asia? Share, tag us, and land on our Wall of!

MarketScreener
Oct 15th, 2026
AstraZeneca strikes up to $1.5 billion AI drug discovery deal with Insitro.

AstraZeneca strikes up to $1.5 billion AI drug discovery deal with Insitro. Published on 10/15/2026 at 08:42 am EDT - Modified on 10/15/2026 at 08:50 am EDT By Adria Calatayud AstraZeneca said it is teaming up with startup Insitro to deploy artificial intelligence to explore new treatments for cardiometabolic diseases in a deal valued at as much as $1.5 billion. The U.K. drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting development and commercial targets, in exchange for the exclusive worldwide rights to advance programs identified as part of the partnership, the companies said Thursday. Insitro will also be eligible to receive royalties based on potential sales, they added. AstraZeneca said the collaboration would focus on difficult-to-treat cardiometabolic diseases such as metabolic dysfunction-associated steatohepatitis, also known as fatty liver disease, and cardiomyopathies. Under the deal, Insitro will use its AI platform to identify the root cause of disease and advance AstraZeneca-nominated targets, the companies said. Insitro said AstraZeneca would lead all clinical development, regulatory work, as well as commercialization activities. The partnership marks the latest to pair pharmaceutical and AI companies, as drugmakers turn to the technology in a bid to speed up the discovery and development of new medicines. Wegovy maker Novo Nordisk last month said it would partner with Anthropic to use the AI lab's science-specific platform, known as Claude Science, for drug research. Rival Roche earlier this year said it would build a supercomputer in partnership with Nvidia. Write to Adria Calatayud at [email protected] (END) Dow Jones Newswires 10-15-26 0835ET (C) Dow Jones - 2026

Red Hot Singapore I Pte. Ltd.
Oct 15th, 2026
AstraZeneca strikes $40 million AI drug discovery deal with insitro.

AstraZeneca strikes $40 million AI drug discovery deal with insitro. 1 hour ago 44 LONDON, Oct 15: AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties. The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said. Insitro will use its "Virtual Human" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials. The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS). It also teamed up with Eli Lilly to build AI models that predict pharmacological properties of small molecules in living organisms. "Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development," Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, told Reuters. "By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late. But when we identify these unique connections early and test them in cellular systems, we're ahead of the game." Barr added that pairing AI tools with experienced scientists allows the company to test fewer molecules in the lab, reduce guesswork and speed the search for effective medicines.

Global Banking & Finance Review
Oct 15th, 2026
AstraZeneca strikes $40 million AI drug discovery deal with insitro.

AstraZeneca strikes $40 million AI drug discovery deal with insitro. Posted on October 15, 2026 · Last updated: October 15, 2026 AstraZeneca and insitro launch $40 million ai-driven drug discovery deal. AI collaboration targets liver and heart diseases. By Patrick Wingrove Overview of the partnership. LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Financial terms and potential milestones. Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties. Focus areas and technology. Targeted diseases: MASH and cardiomyopathies. The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said. AI platform: Virtual Human. Insitro will use its "Virtual Human" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials. Insitro's growing industry presence. Recent partnerships. Bristol Myers Squibb collaboration. The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS). Eli Lilly AI model initiative. It also teamed up with Eli Lilly to build AI models that predict pharmacological properties of small molecules in living organisms. Expert insights. Challenges in drug discovery. "Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development," Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, told Reuters. "By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late. But when we identify these unique connections early and test them in cellular systems, we're ahead of the game." AI and scientific expertise. Barr added that pairing AI tools with experienced scientists allows the company to test fewer molecules in the lab, reduce guesswork and speed the search for effective medicines. (Reporting by Patrick Wingrove in LondonEditing by David Goodman) Key takeaways. * AstraZeneca invests $40 million upfront in AI drug discovery for liver (MASH) and heart (cardiomyopathy) diseases previously lacking effective therapies. * Insitro's Virtual Human(TM) platform combines lab-grown cell models and machine learning to uncover causal disease biology and accelerate target development. * The deal could yield insitro up to $1.46 billion in milestones and royalties, and builds on its growing AI collaboration portfolio with Bristol Myers Squibb and Eli Lilly. Frequently asked questions. What is the focus of the AstraZeneca and insitro partnership? How much is AstraZeneca investing in the insitro deal? What technology will insitro use in the collaboration? Who will conduct clinical trials for the discovered treatments? What diseases are being targeted in this AI-driven drug discovery project?